Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin Data

被引：0
|
作者：
Angelo Del Parigi
Wenbo Tang
Dacheng Liu
Christopher Lee
Richard Pratley
机构：
[1] Boehringer Ingelheim Pharmaceuticals Inc.,
[2] Boehringer Ingelheim GmbH & Co. KG,undefined
[3] Florida Hospital Diabetes Institute,undefined
[4] AdventHealth Translational Research Institute for Metabolism and Diabetes,undefined
来源：
Pharmaceutical Medicine | 2019年 / 33卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
What did this study look at?This study looked at whether a computer program could predict which people with type 2 diabetes would respond best to a particular treatment.The study treatment was a single-pill combination of two medicines, empagliflozin [em-PAH-gli-FLOW-zin] and linagliptin [LYNN-nah-GLIP-tin]. It is used to lower blood sugar (blood glucose) in people with type 2 diabetes.The researchers used machine learning to analyze data from people who received this treatment. Machine learning uses computer models to find patterns in information.The results helped to predict which people might respond best to the treatment.
引用
收藏
页码：209 / 217
页数：8
相关论文
共 50 条
  • [31] Discordance between HbA1c and glycated albumin as glycemic control index in hemodialysis patients with type 2 diabetes mellitus
    Nakamura, Takaaki
    Harada, Natsuki
    Hatta, Tsuguru
    Kashiwagi, Atsunori
    DIABETES, 2007, 56 : A203 - A203
  • [32] Early Combination Therapy with Linagliptin and Metformin in People with Type 2 Diabetes Improves Glycemic Control to HbA1c ≤ 6.5% without Increasing Hypoglycemia: Pooled Analysis of Two Randomized Clinical Trials
    Lv, Qian
    Shen, Jie
    Miao, Lin
    Ye, Binqi
    Schepers, Cornelia
    Plat, Arian
    Shi, Yongquan
    DIABETES THERAPY, 2020, 11 (06) : 1317 - 1330
  • [33] Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions
    Chen, Jingyang
    Yin, Dong
    Dou, Kefei
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [34] Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions
    Jingyang Chen
    Dong Yin
    Kefei Dou
    Cardiovascular Diabetology, 22
  • [35] HbA1c reduction with tirzepatide in people with type 2 diabetes: a mediation analysis using body weight loss as a factor
    Vilsboll, T.
    Nicolay, C.
    Malecki, M.
    Thieu, V. Thuyanh
    Chivukula, K.
    Kiljanski, J.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S324 - S325
  • [36] HbA1c Is Already Not Enough for Glucose Control Assessment in Type 1 and Type 2 Diabetes
    Totomirova, Tzvetelina
    Daskalova, Ivona
    Arnaudova, Mila
    DIABETES, 2019, 68
  • [37] Effects and predictors of a STENO intensive multifactorial intervention for HbA1c target achievement in Taiwanese patients with type 2 diabetes
    Hung, Jui-Yu
    Chen, Yi-Yu
    Koo, Malcolm
    Chiang, Hsin-Hung
    Chen, Pin-Fan
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S170 - S170
  • [38] The Role of Parental Monitoring as a Mediator Between Age and Glycemic Control (HbA1c) in Adolescents With Type 1 Diabetes
    Robinson, Elizabeth M.
    Chen, Rusan
    Powell, Priscilla W.
    Maher, Kathryn E.
    Borschuk, Adrienne P.
    Caccavale, Laura J.
    Kumar, Anil
    Holmes, Clarissa S.
    DIABETES, 2012, 61 : A198 - A199
  • [39] Is the Admission HbA1c Level a Predictor of Glycemic Control and Hospital Complications in General Surgery Patients With Type 2 Diabetes?
    Farrokhi, Farnoosh
    Cardona, Saumeth
    Pasquel, Francisco
    Newton, Christopher
    Smiley, Dawn
    Peng, Limin
    Umpierrez, Guillermo
    DIABETES, 2012, 61 : A213 - A213
  • [40] TREATED TO GLYCEMIC CONTROL TARGET ASSESSED BY FASTING PLASMA GLUCOSE (FPG) AND GLYCATED HEMOGLOBIN (HBA1C) IN PATIENTS WITH TYPE II DIABETES
    Li, Q.
    Bouchard, J. R.
    Wu, N.
    Boulanger, L.
    VALUE IN HEALTH, 2012, 15 (04) : A173 - A173
12345